ADPT - Adaptive Biotechnologies Corporation

NasdaqGS - NasdaqGS Real-time price. Currency in USD
28.10
-0.22 (-0.78%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close28.32
Open27.19
Bid27.00 x 900
Ask29.52 x 1000
Day's range27.10 - 28.58
52-week range24.05 - 55.12
Volume1,362,635
Avg. volume1,209,920
Market cap3.55B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.01
Earnings date25 Feb 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est44.75
  • Here's What Analysts Are Forecasting For Adaptive Biotechnologies Corporation After Its Annual Results
    Simply Wall St.

    Here's What Analysts Are Forecasting For Adaptive Biotechnologies Corporation After Its Annual Results

    Adaptive Biotechnologies Corporation (NASDAQ:ADPT) defied analyst predictions to release its yearly results, which...

  • MEDNAX (MD) Q4 Earnings and Revenues Surpass Estimates
    Zacks

    MEDNAX (MD) Q4 Earnings and Revenues Surpass Estimates

    Mednax's (MD) Q4 results reflect growth in same unit revenues and lower general and administrative expenses.

  • Why Earnings Season Could Be Great for Adaptive (ADPT)
    Zacks

    Why Earnings Season Could Be Great for Adaptive (ADPT)

    Adaptive (ADPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • Top Ranked Momentum Stocks to Buy for December 30th
    Zacks

    Top Ranked Momentum Stocks to Buy for December 30th

    Top Ranked Momentum Stocks to Buy for December 30th

  • Adaptive Biotechnologies Shares March Higher, Can It Continue?
    Zacks

    Adaptive Biotechnologies Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor Adaptive Biotechnologies.

  • Fiverr Languishes Below IPO Price as First Chance to Sell Nears
    Bloomberg

    Fiverr Languishes Below IPO Price as First Chance to Sell Nears

    (Bloomberg) -- Fiverr International Ltd.’s initial zing has almost entirely faded since its June IPO, with the stock falling for six straight days to below its IPO price as insiders’ and early investors’ first chance to sell looms on Tuesday.The biggest stakeholders include Viola Private Equity’s Jonathan Kolber, Deer VII & Co., Accel London III Associates, Square Peg Group, and co-founder and chief executive officer Micha Kaufman, according to data compiled by Bloomberg. But post-IPO stock weakness, with shares off the June high of $44 by more than 52%, make it less likely shareholders will walk away.Fiverr chief Kaufman was unavailable to respond to queries.The operator of an online marketplace for software services had the fourth-best debut of this year’s 239 IPOs, rising a whopping 90% from offer to its first close. That ranks just behind Beyond Meat Inc., Adaptive Biotechnologies Corp., and Cortexyme Inc., each of which has done better hanging on to initial gains. Underwriters on the Fiverr IPO were JPMorgan, Citi, BofA, UBS, Oppenheimer, Needham, and JMP Securities.Analysts appear split, with four buy, three hold and no sell ratings on the stock, according to data compiled by Bloomberg. But with price targets ranging from $22 to $34, they seem to agree that debut highs are unlikely to be seen again anytime soon. To contact the reporter on this story: Crystal Kim in New York at ckim426@bloomberg.netTo contact the editors responsible for this story: Brad Olesen at bolesen3@bloomberg.net, Scott SchnipperFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • 4 Biotech Stocks That Could Keep Beating Wall Street
    Zacks

    4 Biotech Stocks That Could Keep Beating Wall Street

    The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.

  • Illumina (ILMN) Inks Deal to Commercialize NGS-Based IVD Kits
    Zacks

    Illumina (ILMN) Inks Deal to Commercialize NGS-Based IVD Kits

    Illumina (ILMN) aims to expand access to NGS-based IVD test kits and improve patient outcomes through the new partnership deal.

  • Do Insiders Own Shares In Adaptive Biotechnologies Corporation (NASDAQ:ADPT)?
    Simply Wall St.

    Do Insiders Own Shares In Adaptive Biotechnologies Corporation (NASDAQ:ADPT)?

    If you want to know who really controls Adaptive Biotechnologies Corporation (NASDAQ:ADPT), then you'll have to look...

  • Illumina (ILMN) Inks Deal to Develop Distributable Test Kits
    Zacks

    Illumina (ILMN) Inks Deal to Develop Distributable Test Kits

    Illumina (ILMN) aims to expand access to genomic-based testing and improve patient outcome through the new partnership deal.

  • Here's Why Adaptive Biotechnologies Rose 31.9% in August
    Motley Fool

    Here's Why Adaptive Biotechnologies Rose 31.9% in August

    The diagnostic company reported second-quarter 2019 operating results, but shares tumbled in early September.

  • New Listings Stink Up Earnings Season After Reports Disappoint
    Bloomberg

    New Listings Stink Up Earnings Season After Reports Disappoint

    (Bloomberg) -- Shares in three of the year’s hottest IPOs, Uber Technologies Inc., Revolve Group Inc. and Fastly Inc., plunged Friday as the latest batch of newly listed companies reported some of the most disappointing results this earnings season.Uber shares ended Friday 6.8% lower after the ride-hailing company missed sales estimates. Revolve fell 15.6% after the fashion e-tailer reported earnings below expectations. And Fastly, which saw its shares dip below its IPO price intraday, declined 18.1% after reporting lighter than expected margins.The disappointment spread to other IPOs that have not even reported yet, with RealReal Inc. shares tumbling 23% to below its IPO price of $20.Call it an upset, given the hype that tends to follow IPOs. Among the nearly 20 freshly listed companies that reported earnings this week, the majority fell in the next session. IPOs are rising 0.2% on average following reports, lagging behind S&P 500 stocks, which climbed 5.3% on average, according to data compiled by Bloomberg.Other newcomers on deck to report earnings include Adaptive Biotechnologies Corp., Greenlane Holdings Inc., RealReal Inc., and Grocery Outlet Holding Inc. They are among the more well-received IPOs of this year with stocks that opened at least 40% above their offer prices. All are first-time reporters.Cross-border IPOs will be tested as well when China’s big brands So-Young International Inc. and Luckin Coffee Inc. do their show-and-tell.(Updates shares in 1st and 2nd paragraphs, adds RealReal shares in 3rd.)\--With assistance from Drew Singer.To contact the reporter on this story: Crystal Kim in New York at ckim426@bloomberg.netTo contact the editors responsible for this story: Brad Olesen at bolesen3@bloomberg.net, Jennifer Bissell-Linsk, Richard RichtmyerFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.

  • 3 Stocks the World's Best Investors Are Buying Right Now
    Motley Fool

    3 Stocks the World's Best Investors Are Buying Right Now

    This natural gas stock, blood diagnostic company, and gold miner have caught the eye of some of the top investors.

  • Next-Generation Xbox Unveiled as China Production Cuts Loom
    Market Realist

    Next-Generation Xbox Unveiled as China Production Cuts Loom

    Microsoft (MSFT) has unveiled its next-generation video game console in the midst of contemplating Xbox production cuts in China.

  • Why Freeport-McMoRan, Coty, and Adaptive Biotechnologies Slumped Today
    Motley Fool

    Why Freeport-McMoRan, Coty, and Adaptive Biotechnologies Slumped Today

    Despite a strong day for the market, these stocks lagged behind.

  • Recent IPOs show investor appetite is strong for biotechs
    Yahoo Finance

    Recent IPOs show investor appetite is strong for biotechs

    It's a hot market for biotechs.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more